Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Articles by Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCPublished: September 23rd 2020 | Updated:
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCPublished: September 23rd 2020 | Updated:
Practical Management of Early Stage HER2+ Breast CancerPublished: September 23rd 2020 | Updated:
HER2-targeted Therapy: Routes of AdministrationPublished: September 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5